Shots:
Organon & Samsung Bioepis have expanded their development and commercialisation agreement to commercialise a new biosimilar in Australia
As per the deal, Organon will receive exclusive commercial rights to the biosimilar in Australia while Samsung Bioepis will be responsible for full development, manufacturing & regulatory responsibilities
The amended agreement expands their collaboration to 4…
